



#71

Atty. Docket No. 050939/0104

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Peter O'Hanley et al.
Entitled: Immunogenic Pili Presenting Foreign Peptides, Their Production and Use
Appln. No. 09/833,079
Filing Date: April 12, 2001

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Preliminary to examination, please amend the application as follows:

IN THE SPECIFICATION:

Please amend the specification as follows:

After "Brief Description of the Drawings" please replace the descriptions of Figures 2(a) through 5(a) with the following:

Fig. 2(a) provides the *papH* DNA sequence of pHUR849 (SEQ ID NO: 31), Fig. 2(b) pDAL201B *papH* (SEQ ID NO: 33), Fig. 2(c) pDAL210B *papH* (SEQ ID NO: 35), and Fig. 2(d) pDAL200A (SEQ ID NO: 37).

Fig. 3 provides a comparison of the *papH* DNA sequences of pHUR849 (SEQ ID NO: 31), pDAL200A (SEQ ID NO: 37), pDAL201B (SEQ ID NO: 33), and pDAL210B (SEQ ID NO: 35).

Fig. 4 gives a comparison (SEQ ID NO: 39) of deduced amino acid sequences of *papH* genes for pHUR849, pDAL200A, pDAL201B, and pDAL210B.

Fig. 5(a) shows the amino acids (which are underlined) that are deleted from papH in pHUR849 (portion of SEQ ID NO: 32) and Fig. 5(b) shows the amino acids (which are underlined) that are deleted from papH in pDAL201B (portion of SEQ ID NO: 34), pDAL210B (portion of SEQ ID NO: 36), and pDAL200A (portion of SEQ ID NO: 38).

On page 7, after line 20 and before line 26, please replace the paragraph with the following:

<u>F serotype</u>	<u>Structural Pilin Sequence</u>	<u>Residue Position (R)</u>
F13 (SEQ ID NO: 1)	PQGQGVKT	R 5-12
F13 (SEQ ID NO: 2)	AKFGGMGAKKG	R 65-65

REMARKS

In response to the above amendments, examination on the merits is respectfully requested.

Respectfully submitted,

Date

Feb. 28, 2002

By:

Stephen B. Maebius

Stephen B. Maebius
Registration No. 35,264

FOLEY & LARDNER
3000 K Street, N.W., Suite 500
Washington, DC 20007-5109
Phone: (202) 672-5569
Fax: (202) 672-5399

Should additional fees be necessary in connection with the filing of this paper, or if a petition for extension of time is required for timely acceptance of same, the Commissioner is hereby authorized to charge deposit account No. 19-0741 for any such fees; and applicant hereby petitions for any needed extension of time.

MARKED UP VERSION OF THE CHANGES IN THE SPECIFICATION

After "Brief Description of the Drawings" below are the changes to the descriptions of Figures 2(a) through 5(a):

Fig. 2(a) provides the *papH* DNA sequence of pHUR849 (SEQ ID NO: 31), Fig. 2(b) pDAL201B *papH* (SEQ ID NO: 33), Fig. 2(c) pDAL210B *papH* (SEQ ID NO: 35), and Fig. 2(d) pDAL200A (SEQ ID NO: 37).

Fig. 3 provides a comparison of the *papH* DNA sequences of pHUR849 (SEQ ID NO: 31), pDAL200A (SEQ ID NO: 37), pDAL201B (SEQ ID NO: 33), and pDAL210B (SEQ ID NO: 35).

Fig. 4 gives a comparison (SEQ ID NO: 39) of deduced amino acid[e] sequences of *papH* genes for pHUR849, pDAL200A, pDAL201B, and pDAL210B.

Fig. 5(a) shows the amino acids (which are underlined) that are deleted from *papH* in pHUR849 (portion of SEQ ID NO: 32) and Fig. 5(b) shows the amino acids (which are underlined) that are deleted from *papH* in pDAL201B (portion of SEQ ID NO: 34), pDAL210B (portion of SEQ ID NO: 36), and pDAL200A (portion of SEQ ID NO: 38).

On page 7, after line 20, and before line 26, the changes are as follows:

<u>F serotype</u>	<u>Structural Pilin Sequence</u>	<u>Residue Position (R)</u>
F13 (<u>SEQ ID NO: 1</u>)	PQGQ GKVT	R 5-12
F13 (<u>SEQ ID NO: 2</u>)	AKFGGMGAKKG	R 65-65